Osteoporosis Drugs Market Research Reports

"...... mong elders is over 50%, among which nearly 33% suffer from fracture. It is estimated that the number of osteoporosis patients and patients with low bone mass will rise to 280 million by 2020. Hence osteoporosis drugs' promising future. Alend......"

"...... ced mobility and life quality caused by joint pain, malformation and joint dysfunction. First developed by Gloria Pharmaceuticals Co., Ltd, cervus and cucumis polypeptide is a sterile water solution made of extracted bones of Cervus Nippon Te......"

"...... . Meanwhile, patients with lung cancer also need to pay attention to bone metastases despite their short median survival due to lung cancer's high incidence. The complications of bone metastases include bony pain, pathological fracture, spinal cord c......"

"...... sult in severe lesions in bone including such skeletalrelated events as bone pain, pathological fracture, spinal cord compression and hypercalcemia. Once Bone metastasis occurs, most patients will suffer from different degrees of pain even pathologic......"

"...... gainst bone resorption, belongs to the second generation of selective estrogen receptor modulator (SERMs). Different from traditional estrogen replacement therapy (ERT) or hormone replacement therapy (HRT), raloxifene can not only prevent postmenopau......"

"...... 12.4% and that this figure among women aged 50 and above is 50%. It is estimated that the number of osteoporosis patients and patients with low bone mass will rise to 280 million by 2020. Currently, drugs for the prevention and treatment of o......"